Thailand has taken a major step in its healthcare journey as the Chulabhorn Royal Academy (CRA) launches Imcranib 100 for ...

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib ...

Thailand has produced its first locally developed targeted therapy pill for cancer treatment. Imcranib 100 is the result of the scientific vision and leadership of Her Royal Highness Princess ...

Thailand has introduced its first domestically created targeted therapy pill for cancer treatment, named Imcranib 100.

Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI ...

Italy’s Robin Foà, MD, an iconic European clinician-researcher, has been at forefront of hematology’s transformation for half ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

"Imcranib 100", the first targeted cancer drug in tablet form developed and produced in Thailand, is the result of the ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

Imatinib (STI571 or CGP57148B) is an innovative treatment for tumours with a constitutively activated form of c-ABL, c-KIT, or PDGFR. Such tumours include Philadelphia-chromosome-positive (Ph-positive ...

Imatinib has shown robust and durable efficacy for the front-line treatment of gastrointestinal stromal tumours (GIST).1 However, long-term use of imatinib is often limited by side-effects, medical ...